NCT07530224

JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Shixiu Wu · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Currently, the principal strategy for immune checkpoint inhibitors (ICI)-related dermatitis include systemic use of corticosteroids, which can impair the efficacy of preceding ICIs treatment. Janus kinase inhibitors (JAKi) could be the optimal option for ICI-related dermatitis, which can not only provide rapid relief for ICI-related dermatitis but also potentially enhance the anti-tumor efficacy of ICIs with minimal adverse events. This is an open-lable, phase II trial, aims to evaluate efficacy and safety of JAK inhibitors for solid malignant tumor patients with refractory ICI-related dermatitis.

Conditions

• Immune Checkpoint Inhibitor-Induced Dermatitis

Interventions

Type	Name	Description
DRUG	treated with JAK inhibitors orally for 28 days	treated with JAK inhibitors (upadacitinib 15mg qd/tofacitinib 5mg bid)orally for 28 days

Timeline

• Start date: 2026-03-25
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2026-04-15
• Last updated: 2026-04-15

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study